HP Kit is a combination pharmaceutical formulation containing Omeprazole 20 mg, Tinidazole 500 mg, and Amoxycillin 750 mg, indicated primarily for the eradication of Helicobacter pylori infection associated with peptic ulcer disease and gastritis. Omeprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, thereby creating a less acidic environment conducive to antibiotic efficacy and mucosal healing. Tinidazole, a nitroimidazole antimicrobial agent, exhibits potent activity against anaerobic bacteria and protozoa, targeting the anaerobic component of H. pylori infection. Amoxycillin, a broad-spectrum beta-lactam antibiotic, inhibits bacterial cell wall synthesis, contributing to the eradication of H. pylori by targeting susceptible strains. The combined use of these agents enhances treatment efficacy by addressing multiple pathogenic mechanisms. HP Kit is typically administered as part of a triple therapy regimen, with dosing and duration determined by clinical guidelines and patient-specific factors. Caution is advised in patients with hypersensitivity to penicillins, nitroimidazoles, or proton pump inhibitors. Common adverse effects may include gastrointestinal disturbances, headache, and hypersensitivity reactions. This combination therapy should be used under medical supervision to ensure optimal outcomes and minimize resistance development.